EX-10.49 22 dex1049.htm BUY-IN LICENSE AGREEMENT BUY-IN LICENSE AGREEMENT MASIMO CORPORATION — MASIMO INTERNATIONAL HOLDINGSBuy-in License Agreement • May 5th, 2020 • California
THIS BUY-IN LICENSE AGREEMENT (the “Agreement”) is effective as of the date of execution (the “Effective Date”), by and between Masimo Corporation (“Masimo US”), a Delaware corporation having its principal place of business at 40 Parker, Irvine, CA 92618, and Masimo International Holdings (“Masimo Cayman”), a Cayman Islands corporation having its registered office at 75 Fort Street, P.O. Box 1350, Grand Cayman, KY 1-1108 Cayman Islands (collectively, the “Parties” and individually, “Party”).
AMENDED AND RESTATED BUY-IN LICENSE AGREEMENT between ARIAD Pharmaceuticals, Inc. and ARIAD Pharmaceuticals (Europe) Sarl and Incyte Corporation (as guarantor)Buy-in License Agreement • February 13th, 2017 • Ariad Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED BUY-IN LICENSE AGREEMENT (“Agreement”) dated as of June 1, 2016 (the “Effective Date”), between ARIAD Pharmaceuticals, Inc., (“ARIAD US”), a Delaware corporation and ARIAD Pharmaceuticals (Europe) Sarl, (“ARIAD SWISSCO”), a Swiss limited liability company registered in Lausanne (together, the “Parties” and, individually, each a “Party”) and Incyte Corporation, a Delaware corporation (“Incyte Corporation”) solely in its capacity as guarantor under Section 30.19. This Agreement only comes into effect on the Effective Date (as defined below) and shall be of no force or effect if there is no Closing (as defined below).
EX-10.3 2 a17-3826_1ex10d3.htm EX-10.3 CONFIDENTIAL TREATMENT MATERIALBuy-in License Agreement • May 5th, 2020 • New York
CONFIDENTIAL TREATMENT REQUESTED: Information for which confidential treatment has been requested is omitted and is noted with asterisks. An unredacted version of this document has been filed separately with the Securities and Exchange Commission (the “Commission”).
AMENDED AND RESTATED BUY-IN LICENSE AGREEMENT between ARIAD Pharmaceuticals, Inc. and ARIAD Pharmaceuticals (Europe) Sarl and Incyte Corporation (as guarantor)Buy-in License Agreement • August 9th, 2016 • Incyte Corp • Services-commercial physical & biological research • New York
THIS AMENDED AND RESTATED BUY-IN LICENSE AGREEMENT (“Agreement”) dated as of June 1, 2016 (the “Effective Date”), between ARIAD Pharmaceuticals, Inc., (“ARIAD US”), a Delaware corporation and ARIAD Pharmaceuticals (Europe) Sarl, (“ARIAD SWISSCO”), a Swiss limited liability company registered in Lausanne (together, the “Parties” and, individually, each a “Party”) and Incyte Corporation, a Delaware corporation (“Incyte Corporation”) solely in its capacity as guarantor under Section 30.19. This Agreement only comes into effect on the Effective Date (as defined below) and shall be of no force or effect if there is no Closing (as defined below).
